GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

GSK's drive to resurrect its multiple myeloma ... MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Discover how AI is transforming the pharma commercial ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...